Longevity & Aging · Metabolic & Cardiometabolic
testosterone therapy does not increase prostate cancer risk
In plain terms: Is testosterone therapy safe for the prostate?
Part of: 💊 Testosterone therapy (TRT)
On the cancer question, the modern evidence is reassuring: the old fear that testosterone feeds prostate cancer is not supported. Randomized trials, large registries, and even prostate-cancer-survivor studies show no increased risk, and some show lower risk. The main caveat is that the trials weren't long enough to be the final word, so men on testosterone should still get routine PSA/prostate monitoring.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
The old fear that testosterone therapy **causes or fuels prostate cancer** is **not supported by the evidence** — a genuine reversal of decades of dogma. Randomized safety data (TRAVERSE), multiple meta-analyses, the RHYME registry, and large SEER-Medicare cohorts show **no increased prostate-cancer risk**, and some even find lower risk; small trials in prostate-cancer survivors show no recurrence
The evidence (16)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Nigro N, Christ-Crain M 2012 · Swiss Med Wkly | mechanism | mixed | low | Review: no clear causative role established, but flags a meta-analysis with higher prostate-event rates in elderly TRT-treated men - urges caution. |
| Debruyne FMJ et al. 2017 · BJU Int | observational | supports | moderate | RHYME prospective registry (n=999): positive-biopsy proportion near-identical in TRT (37.5%) vs no-TRT (37.0%). |
| Kardoust Parizi M et al. 2019 · Investig Clin Urol | meta-analysis | supports | moderate | SR/meta 21 studies: biochemical-recurrence rate after TRT in prostate-cancer survivors only 1%; no harm signal. |
| Morgentaler A, Traish AM 2011 · Eur Urol | mechanism | supports | low | Saturation-model review (Morgentaler network): higher serum T not associated with prostate-cancer risk; androgen-receptor saturation. [originator's own review - down-weighted] |
| Abdelgadir E et al. 2024 · Cancers (Basel) | observational | supports | high | SEER-Medicare (105,690 men): pre-diagnostic TRT associated with reduced incidence of prostate cancer and aggressive disease. |
| Morgentaler A 2009 · Eur Urol | mechanism | supports | low | Review (Morgentaler network): low (not high) serum T associated with worse prostate-cancer features. [originator's own review - down-weighted] |
| Hussain SA et al. 2024 · Cancer | observational | supports | high | SEER-Medicare (41,707 men): pre-diagnostic TRT associated with lower prostate-cancer-specific mortality; no adverse signal. |
| Wallis CJD et al. 2016 · Lancet Diabetes Endocrinol | observational | supports | high | Ontario registry (10,311 TRT / 28,029 controls): long-term TRT associated with reduced prostate-cancer diagnosis (highest-tertile HR 0.60). |
| Isbarn H, Morgentaler A et al. 2009 · Eur Urol | mechanism | supports | low | Review (Morgentaler network): serum androgens not associated with prostate-cancer risk across a broad range. [originator's own review - down-weighted] |
| Cui Y et al. 2014 · Prostate Cancer Prostatic Dis | meta-analysis | supports | moderate | Meta 22 RCTs (n=2351): no significant increase in prostate cancer across routes; modest short-term PSA rise. |
| Bhasin S et al. 2024 · J Clin Endocrinol Metab | RCT | supports | high | TRAVERSE (n=5204): high-grade prostate cancer 0.19% (TRT) vs 0.12% (placebo), HR 1.62 (ns); no significant difference in any prostate endpoint. |
| Kang DY et al. 2015 · Medicine (Baltimore) | meta-analysis | supports | moderate | Meta 15 studies: modest PSA rise (+0.15 ng/mL) but similar elevated-PSA odds (OR 1.02, ns). |
| Santucci C et al. 2025 · World J Urol | meta-analysis | supports | moderate | SR 19 observational studies: biochemical-recurrence 0-7% in TRT-exposed localized-PCa cohorts; cautious oncological safety pending RCTs. |
| Elliott J et al. 2017 · BMJ Open | meta-analysis | supports | moderate | Network meta 87 RCTs + 51 NRS: no statistically significant increase in prostate cancer; short durations limit long-term conclusions. |
| Bhasin S et al. 2026 · J Urol | RCT | supports | moderate | RCT (136 prostate-cancer survivors post-prostatectomy): 12wk TRT gave zero biochemical recurrences in either arm. |
| Garcia-Becerra CA et al. 2026 · Int J Impot Res | meta-analysis | supports | high | Meta 41 RCTs (n=11,161): TTh not associated with increased prostate-cancer events (OR 0.88) or clinically-significant prostate cancer (OR 1.13, both ns) - reinforces no-increased-risk. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.